Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ArriVent BioPharma (AVBP) Operating Expenses (2023 - 2026)

ArriVent BioPharma has reported Operating Expenses over the past 4 years, most recently at $46.1 million for Q1 2026.

  • Quarterly results put Operating Expenses at $46.1 million for Q1 2026, down 30.94% from a year ago — trailing twelve months through Mar 2026 was $156.9 million (up 11.73% YoY), and the annual figure for FY2025 was $177.5 million, up 88.25%.
  • Operating Expenses reached $46.1 million in Q1 2026 per AVBP's latest filing, up from $38.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $66.8 million in Q1 2025 and bottomed at $12.2 million in Q1 2023.
  • Median Operating Expenses over the past 4 years was $24.2 million (2024), compared with a mean of $30.2 million.
  • The largest annual shift saw Operating Expenses surged 222.98% in 2025 before it plummeted 30.94% in 2026.
  • Over 4 years, Operating Expenses stood at $23.1 million in 2023, then grew by 2.54% to $23.7 million in 2024, then soared by 63.78% to $38.8 million in 2025, then rose by 18.77% to $46.1 million in 2026.
  • Business Quant data shows Operating Expenses for AVBP at $46.1 million in Q1 2026, $38.8 million in Q4 2025, and $38.3 million in Q3 2025.